Phases précoces tumeurs solides MCLA-158-CL01 Phase 1 Dose Finding Study Evaluating the Bispecific Antibody MCLA-158 in Metastatic Colorectal Cancer and Other Advanced Solid Tumors. Paris CHRISTOPHE LE TOURNEAU
Phases précoces tumeurs solides GCT1047-01 First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1047 in Subjects With Malignant Solid Tumors. Paris CHRISTOPHE LE TOURNEAU
Phases précoces tumeurs solides LCB-1801-001 A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY OF NI-1801, A BISPECIFIC MESOTHELIN x CD47 ENGAGING ANTIBODY,IN PATIENTS WITH MESOTHELIN EXPRESSING SOLID CANCERS. Paris EMANUELA ROMANO
Appareil pulmonaire M20-111 A Phase 1 First In Human Study Evaluating Safety And Efficacy Of ABBV-637 As Either Monotherapy Or In Combination In Adult Subjects With Relapsed And Refractory Solid Tumors Paris CHRISTOPHE LE TOURNEAU
Phases précoces tumeurs solides GO30103 (TIGIT) A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors. Paris EMANUELA ROMANO
Appareil pulmonaire CHRYSALIS-2 (73841937NSC1001 ) An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-;73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in;Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in;Participants With Advanced Non-Small Cell Lung Cancer Paris NICOLAS GIRARD
Phases précoces tumeurs solides CLEVER-PEPTIDE (IC 2018-06) Open-label, non-controlled, multicenter, dose escalation, first-in-human phase I clinical trial to evaluate the safety, pharmacokinetics and preliminary antitumor activity of intravenous PEP-010, administered as single agent and in combination with paclitaxel in patients with recurrent and/or metastatic solid cancer. Paris CHRISTOPHE LE TOURNEAU
Phases précoces tumeurs solides EMBER (J2J-MC-JZLA) EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers. Paris JEAN-YVES PIERGA